Biogen chief sells 12K shares; Sovaldi cures hep C in HIV patients;

@FiercePharma: Tops this weekend: AbbVie finally gets Shire, its low tax base and enough new drugs to protect its future. News | Follow @FiercePharma

@TracyStaton: CVS Caremark lays out case for new specialty-drug pricing approach in JAMA editorial. More | Follow @TracyStaton

@EricPFierce: ICYMI: Teva says it is cooperating with probe by Israel into source of blood infections taking Teva product. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: Allergan plotting 1,500 job cuts as part of restructuring. Release | Follow @CarlyHFierce

> Biogen Idec ($BIIB) CEO George Scangos sold 12,316 shares of the company's stock on the open market in a transaction dated July 16. Report

> Gilead's ($GILD) Sovaldi cures hepatitis C in patients with HIV, a new study says. Report

> Bank Exane BNP Paribas sees at least a 50% chance that Pfizer ($PFE) will return with a sweetened offer for AstraZeneca ($AZN) after its failed takeover earlier this year. Story

> Eli Lilly ($LLY) is expanding its diabetes treatment portfolio in India. Report

> Medicare has scaled back its restrictions on hospice drugs. Report

> India's pharma exports to the U.S. are expected to be high after dropping last year on FDA actions against manufacturers. More

Medical Device News

@FierceMedDev: Stryker delivers positive Q2 numbers but stays mum on inversion. ICYMI Friday | Follow @FierceMedDev

@MichaelGFierce: Delivering breast cancer drug through the skin grants disease prevention. FierceDrugDelivery article | Follow @MichaelGFierce

@VarunSaxena2: Venture capitalist spending bonanza lifts med tech investment in Q2. Report | Follow @VarunSaxena2

@EmilyWFierce: DC journo raises $75K on Kickstarter to fly drones over factory farms, circumvent "ag-gag" laws. More from NPR | Follow @EmilyWFierce

> MIT device could give arthritics and others a helping hand with extra fingers. Story

> Miss Idaho wears insulin pump in swimsuit competition. Item

> Patient groups argue for faster med tech FDA approvals at industry meeting. Article

Biotech News

@FierceBiotech: Will AbbVie now emerge as the next megamerger target? More | Follow @FierceBiotech

@JohnCFierce: New Science Ventures joins the biotech VC boom, plots $100M fund. News | Follow @JohnCFierce

@DamianFierce: Cutting jobs, ditching "unpromising" R&D programs -- $AGN is slowly becoming the company $VRX wants it to be. Just, you know, minus $VRX. | Follow @DamianFierce

@EmilyMFierce: What?! Update on the Found Vials: There Weren't 6; There Were 327. (Not All of Them Were Smallpox.) More from Wired | Follow @EmilyMFierce

> Allergan aims ax at R&D, eliminating 1,500 jobs in bitter takeover fight. Report

> Cerecor raises $16M for PhII study of 'Special K' depression remedy. Article

> J&J partner Aduro grabs an FDA 'breakthrough' nod for its immuno-oncology combo. News

CRO News

> Amid global expansion, India's GVK focuses on clinical development. Story

> CRO Chiltern snags rival Ockham to bolster its oncology footprint. Report

> Post-buyout Harlan inks a CRO partnership with Fluofarma. Article

> Theorem eyes an Indian expansion with latest partnership. Story

> Catalent shoots for $872M in a blockbuster IPO. News

Biotech IT News

> Google-backed service provider gives clients direct control of robot-run lab. Report

> FDA adds recalls API as openFDA initiative gathers pace. News

> Bioinformatics skills help Codexis strike $25M deal with GSK. Story

> Report: Development IT hit hard in Novartis cutbacks. Article

> Novartis and Google team up to commercialize 'smart' contact lenses. Item

Animal Health News

> Seizures in horses in Kentucky focus attention on drug compounding. More

> Virbac H1 sales hurt by Iverhart recall in U.S. Report

> Sanofi's Merial revives heartworm treatment. Article

> Why is there increased activity in animal health IPOs? Item

> France's AB Science warned by FDA for its canine cancer drug promotion. Story

> Merck prods cattle producers to help it test the safety of withdrawn Zilmax. Article

And Finally... A judge has found Pfizer ($PFE) responsible for $1.7 million in sewer payments. Story

Suggested Articles

An online pharmacy has again criticized FDA action after tipping off regulators to the existence of a dangerous impurity in Zantac and other antacids.

A group of senators is asking the FTC to take a careful look at pharma mergers given the cost of drugs in the U.S.

Life’s been tough for J&J's prostate cancer med Erleada in its battle with Pfizer-Astellas’ Xtandi. A new FDA nod could help level the playing field.…